Skip to main content

Table 1 Demographics and CSF characteristics of DLB patients and controls

From: Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach

 

Cohort 1 (n = 40)

Cohort 2 (n = 30)

Cohort 3B (n = 76)#

DLB (n = 20)

Controls (n = 20)

DLB (n = 17)

Controls (n = 13)

DLB (n = 48)

Controls (n = 28)

Age, yr

range [min-max]

65.3 ± 5.8

[54.1–76.5]

65.1 ± 5.4

[53.9–74.0]

66.9 ± 7.5

[53.9–74.0]

65.6 ± 8.5

[52.4–76.7]

67.8 ± 6.3*

[54.1–78.4]

64.1 ± 5.8

[53.9–74.0]

Male sex

17 (85%)

17 (85%)

13 (76%)

9 (69%)

42 (88%)

24 (86%)

Symptom duration, yr

3 [2–4]

N/A

2 [2–4]

N/A

2 [1–4]

N/A

MMSE

23 [21–26]***

28 [27–29]

26 [21–28]*

29 [28–30]

23 [21–26]***

28 [27–30]

CSF AD biomarkers

Aß1–42, (pg/ml)

Abnormal

846 [637–1011]

0 (0%)

820 [691–1039]

0 (0%)

611 [478–942]*

8 (47%)

959 [932–1054]

0 (0%)

660 [536–871]**

13 (27%)

856 [691–1027]

0 (0%)

total tau, (pg/ml)

Abnormal

238 [200–286]

0 (0%)

209 [167–266]

0 (0%)

317 [268–599]**

8 (47%)

226 [194–253]

0 (0%)

299 [224–370]***

11 (23%)

190 [156–257]

0 (0%)

p-tau, (pg/ml)

Abnormal

37 [29–47]

0 (0%)

42 [31–47]

0 (0%)

46 [41–71]

7 (41%)

41 [37–49]

0 (0%)

47 [34–61]*

18 (37%)

38 [28–46]

0 (0%)

APOE ε4 carrier

9 (45%)

8 (40%)

10 (71%)**

2 (17%)

25 (55%)

10 (38%)

  1. Data are presented as mean ± SD for normally distributed continuous variables, as median [first quartile – third quartile] for non-normally distributed continuous variables or as n (%) for categorical variables
  2. CSF cutoff values were set on Aß1–42 < 550 pg/ml, total tau > 375 pg/ml, p-tau > 52 pg/ml [17]
  3. Differences between DLB patients and controls were assessed with Student’s t-test, Wilcoxon signed-rank test or Fisher’s Exact Test.* p < 0.05, ** p < 0.01, *** p < 0.001
  4. #NPTX2 ELISA: n = 76 (DLB: n = 48, Controls: n = 28); VGF ELISA: n = 66 (DLB: n = 44, Controls: n = 22); VGF SRM: n = 65 (DLB: n = 44, Controls: n = 21)
  5. Abbreviations: Aß1–42 ß-Amyloid 1–42, AD Alzheimer’s disease, APOE Apoliproprotein E, CSF Cerebrospinal fluid, DLB Dementia with Lewy bodies, MMSE Mini mental State examination (score range 0–30), N/A Not applicable, p-tau Tau phosphorylated at threonine 181
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326